Five years experience with Raltegravir in a large HIV centre
Clare van Halsema1, Tom Whitfield2, Naomi Lin3, Kathryn Millington4, Andrew Thompson2, Adele Gothard4, Andrew Ustianowski1

1North Manchester General Hospital, UK 2Manchester Medical School, UK

**Background**
- Raltegravir (RAL) is the first integrase strand transfer inhibitor (INSTI) active against HIV in clinical use as a component of antiretroviral therapy (ART)
- It was licensed by European Medicines Agency in December 2007
- Real life ART experience is informative and complements trial data
- We aimed to evaluate our use of RAL in naive and experienced patients, including those with hepatitis and mycobacterial co-infections and off-license use

**Methods**
- Pharmacy data and the departmental HIV database were used to identify all patients who had taken at least one dose of RAL, up to 30 November 2012, outside of clinical trials
- A standardised reporting form was used to extract data from clinical and laboratory records

**Demographics of patient group**
- 215 individuals with HIV-1 infection provided 502 patient-years of RAL experience, with characteristics shown in table:

<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>Female</th>
<th>Transgender</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%)</td>
<td>166 (77%)</td>
<td>48 (22%)</td>
<td>1 (0.5%)</td>
<td>215 (100%)</td>
</tr>
<tr>
<td>Median age (IQR)</td>
<td>45 (38, 51)</td>
<td>38 (33, 43)</td>
<td>43 (37, 49)</td>
<td></td>
</tr>
<tr>
<td>Caucasian n (%)</td>
<td>144 (87%)</td>
<td>10 (21%)</td>
<td>155 (72%)</td>
<td></td>
</tr>
<tr>
<td>African/Caribbean n (%)</td>
<td>19 (11%)</td>
<td>35 (79%)</td>
<td>- 54 (25%)</td>
<td></td>
</tr>
<tr>
<td>Other ethnicity</td>
<td>3 (2%)</td>
<td>3 (6%)</td>
<td>- 6 (3%)</td>
<td></td>
</tr>
</tbody>
</table>

- Median duration of RAL use 2.6 years (interquartile range [IQR] 0.8, 3.5)

**Previous antiretroviral therapy (ART)**
- 189 (88%) ART-experienced, with median CD4 323 cells/µL (IQR 132, 569 )
- 26 (12%) ART-naive, with median CD4 54 cells/µL (IQR 23, 258)
- Of 51 patients not on ART at the time of starting RAL, median HIV viral load (VL) was 66650 copies/mL (range 565, 8647191)

**Why switch/add RAL?**
189 experienced patients had 217 reasons for starting RAL
- Naive patients chose RAL for rapid VL reduction (14/26) or avoiding DDI (13/26)
- Of 51 patients not on ART at the time of starting RAL, median HIV viral load (VL) was 66650 copies/mL (range 565, 8647191)

**Why stop?**
- 71 stopped RAL – reasons clear in 70/71
- Toxicity: 1 with acute hepatitis due to RAL; 3 with headaches

**Hepatitis co-infection**
- 35 individuals providing 92 patient-years on RAL
- 21 hepatitis B sAg+ and 14 hepatitis C RNA+

**Integrase resistance after virological failure**
- 10/215 (5%) stopped RAL due to virological failure:
  - 6 had low level viraemia precluding sequencing or failed sequencing
  - 4 stopped RAL due to side effects (peripheral neuropathy)

**Pregnancy**
- 6 women took RAL during pregnancy
- 5/6 added RAL to existing regimen (treatment intensification), at median 32 weeks gestation. One switch from protease inhibitor for tolerability
- All VL <40 at delivery, all infants HIV negative, no foetal abnormalities

**Mycobacterial co-infection**
- 22 individuals: 9/22 (41%) male; 17/22 (77%) African/Caribbean
- Median VL in 11/22 not on ART on starting RAL: 109833 copies/mL
- 3 with K103N at baseline and 1 with G190S
- Median CD4 count in all 22: 83 cells/µL

**Results**
- One patient stopped RAL due to virological failure
- One stopped RAL due to side effects (peripheral neuropathy)

**Hepatitis co-infection**
- 21 with hepatitis B infection
- 14 with hepatitis C infection

**Conclusions**
- RAL appears safe in clinical practice, with no excess toxicity seen above that reported in clinical trials
- RAL was used safely and effectively in pregnancy and with hepatitis and mycobacterial co-infections
- Once daily dosing is effective where adherence is good
- INSTI resistance on failure occurred in those with pre-existing resistance to other classes

19th Conference of the British HIV Association, Manchester, April 2013. Poster number P149.